1991
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal response
1979
Chemotherapy of Hodgkin's disease
Young R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.Peer-Reviewed Original ResearchConceptsAdvanced diseaseHodgkin's diseaseModality approachSuch long-term complicationsIIIB Hodgkin's diseaseInduction chemotherapy regimensPrimary induction failureShort initial remissionAdvanced Hodgkin's diseaseDisease-free survivalOverall survival ratePrognosis of patientsLong-term complicationsInduction failureAggressive therapyChemotherapy regimensComplete remissionInitial remissionLate complicationsSecond malignanciesCombination chemotherapySurvival benefitMOPP regimenActual survivalCombined modality
1978
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Johnson R, Canellos G, Young R, Chabner B, DeVita V. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Journal Of The National Cancer Institute 1978, 62: 321-5. PMID: 580598.Peer-Reviewed Original ResearchConceptsTotal body irradiationTotal body irradiation patientsEvaluate new therapeutic approachesSurvival rateStage III-IVCandida sepsisDurable remissionsLymphocytic lymphomaBody irradiationMalignant lymphomaSevere granulocytopeniaMyeloproliferative disordersLate complicationsIII-IVChemotherapy complicationsInduction treatmentSurvival advantageNeurotoxic reactionsTherapeutic approachesLymphomaChemotherapyPatientsComplicationsRadiotherapySurvival